Tina S. Morris, PhD

home / authors / tina-s-morris-phd-1

Tina S. Morris, PhD, is vice president of Biologics & Biotechnology at United States Pharmacopeia (USP)

Articles

Diversifying the Global Heparin Supply Chain: Reintroduction of Bovine Heparin in the United States?

Diversifying the Global Heparin Supply Chain: Reintroduction of Bovine Heparin in the United States?

Anita Szajek;Elaine Gray;David Keire;Barbara Mulloy;Ali Al-Hakim;Christina Chase;Monica Da Luz Carvalho Soares;Damian Cairatti;John Hogwood;Paulo Mourão;Tina S. Morris, PhD
November 2nd 2015

The global supply chain for bovine and porcine heparin and regulatory considerations are examined.

Site Logo

USP Publishes Monoclonal Antibody Guidelines

Anita Y. Szajek, PhD;Fouad Atouf, PhD;Dale Schmidt, M.S.;Tina S. Morris, PhD
March 2nd 2015

A General Chapter on mAbs will be published in USP-NF as biologics increase their role in healthcare.

i4-787759-1408598443976.jpg

USP Further Strengthens Quality Standards for Heparin

Tina S. Morris, PhD
September 2nd 2012

USP optimizes identification tests and impurities procedures.

i1-734112-1408616638788.jpg

Inside USP: International Dialogue on Biologics Standards

Tina S. Morris, PhD
August 2nd 2011

USP promotes horizontal standards for biologics' quality attributes.

i1_t-632995-1408646076615.gif

Inside USP: Characterization of Heparin Products

Tina S. Morris, PhD
October 2nd 2009

USP workshop participants support new methods to safeguard heparin products but desire international harmonization. This article contains bonus online-exclusive material.

i1-584976-1408657008885.jpg

Inside USP: Heparin Monographs Further Revised

Tina S. Morris, PhD
March 2nd 2009

USP's Stage 2 heparin monograph revisions address identification, potency, and impurities.

Latest Updated Articles

Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs
Published: April 21st 2025 | Updated: June 17th 2025
Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs
3d rendering of Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells | Image Credit: © Love Employee - © Love Employee- stock.adobe.com
Published: February 4th 2025 | Updated: March 3rd 2025
Advancing ADCs to the Next Level
CPHI Milan 2024: New Developments in ADC Technologies
Published: October 10th 2024 | Updated: March 3rd 2025
CPHI Milan 2024: New Developments in ADC Technologies
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
Published: January 10th 2025 | Updated: January 13th 2025
Cavazzoni Retires as CDER Director
Buy, Sell, Hold: Cell and Gene Therapy
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists